Video

Concierge Medicine and Cardiac Care During COVID-19

Author(s):

What does personalized outpatient care look like for a cardiology institute during the pandemic?

Now that the coronavirus 2019 (COVID-19) pandemic has altered the US healthcare system in such severe ways, a continued topic across all specialties has been on what will last, and what will return. Facets of telemedicine seem to have been embraced by physicians, patients, and payers alike; other quick fixes, not so much.

What about systems that were already designed to work in the system set by a viral pandemic? Take, for example, the collaboration between The Heart House and GoMo Health.

Through a partnership between the latter group and the American Heart Association Center for Innovation and Technology, the teams were able to establish a Heart Failure Digital Therapeutic program at the South New Jersey facility that continues engagement between patients and caregivers post-discharge, and aims to bring 4 improvements to their virtual outpatient care:

  1. Reduced costs
  2. Better outcomes
  3. Improved satisfaction
  4. Increased joy in clinical practice

In brief time, cardiac hospital readmissions have dropped by nearly two-thirds and appointments have increased by 10%.

How is this collaborative model applicable to the level of cardiac care necessary in a telemedicine-heavy system during COVID-19?

In a panel-discussion interview with HCPLive®, The Heart House interventional cardiologist Sanford Gips, MD, executive director Josh Ginsberg, MS, and GoMo Health chief behavioral technologist Bob Gold discussed virtual concierge medicine and how applicable such a system is across other institutions.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.